The MAGEC System for Spinal Lengthening in Children with Scoliosis: A NICE Medical Technology Guidance

被引:43
|
作者
Jenks M. [1 ]
Craig J. [1 ]
Higgins J. [2 ]
Willits I. [3 ]
Barata T. [4 ]
Wood H. [1 ]
Kimpton C. [3 ]
Sims A. [3 ]
机构
[1] York Health Economics Consortium, University of York, Level 2, Market Square, York
[2] National Institute for Health and Care Excellence, Level 1A, City Tower, Piccadilly Plaza, Manchester
[3] Newcastle upon Tyne Hospitals NHS Foundation Trust, Freeman Hospital, Freeman Road, Newcastle upon Tyne
[4] Quantics Consulting Ltd, West End House, 28 Drumsheugh Gardens, Edinburgh
关键词
Cobb Angle; Device Failure; Economic Evidence; External Assessment Centre; Medical Technology Advisory Committee;
D O I
10.1007/s40258-014-0127-4
中图分类号
学科分类号
摘要
Scoliosis—structural lateral curvature of the spine—affects around four children per 1,000. The MAGEC system comprises a magnetically distractible spinal rod implant and an external remote controller, which lengthens the rod; this system avoids repeated surgical lengthening. Rod implants brace the spine internally and are lengthened as the child grows, preventing worsening of scoliosis and delaying the need for spinal fusion. The Medical Technologies Advisory Committee at the National Institute for Health and Care Excellence (NICE) selected the MAGEC system for evaluation in a NICE medical technologies guidance. Six studies were identified by the sponsor (Ellipse Technologies Inc.) as being relevant to the decision problem. Meta-analysis was used to compare the clinical evidence results with those of one conventional growth rod study, and equal efficacy of the two devices was concluded. The key weakness was selection of a single comparator study. The External Assessment Centre (EAC) identified 16 conventional growth rod studies and undertook meta-analyses of relevant outcomes. Its critique highlighted limitations around study heterogeneity and variations in baseline characteristics and follow-up duration, precluding the ability to draw firm conclusions. The sponsor constructed a de novo costing model showing that MAGEC rods generated cost savings of £9,946 per patient after 6 years, compared with conventional rods. The EAC critiqued and updated the model structure and inputs, calculating robust cost savings of £12,077 per patient with MAGEC rods compared with conventional rods over 6 years. The year of valuation was 2012. NICE issued a positive recommendation as supported by the evidence (Medical Technologies Guidance 18). © 2014, The Author(s).
引用
收藏
页码:587 / 599
页数:12
相关论文
共 50 条
  • [41] NICE Medical Technologies Guidance A Novel and Rigorous Methodology to Address a New Health Technology Assessment Challenge
    Campbell, Bruce
    Campbell, Mark
    APPLIED HEALTH ECONOMICS AND HEALTH POLICY, 2012, 10 (05) : 295 - 297
  • [42] Impact of the National Institute for Health and Care Excellence (NICE) guidance on medical technology uptake: analysis of the uptake of spinal cord stimulation in England 2008-2012
    Vyawahare, Bharati
    Hallas, Natalie
    Brookes, Morag
    Taylor, Rod S.
    Eldabe, Sam
    BMJ OPEN, 2014, 4 (01):
  • [43] Axonics Sacral Neuromodulation System for Treating Refractory Overactive Bladder: A NICE Medical Technologies Guidance
    Ruth Louise Poole
    Megan Dale
    Helen Morgan
    Tosin Oladapo
    Rebecca Brookfield
    Rhys Morris
    Applied Health Economics and Health Policy, 2022, 20 : 305 - 313
  • [44] Axonics Sacral Neuromodulation System for Treating Refractory Overactive Bladder: A NICE Medical Technologies Guidance
    Poole, Ruth Louise
    Dale, Megan
    Morgan, Helen
    Oladapo, Tosin
    Brookfield, Rebecca
    Morris, Rhys
    APPLIED HEALTH ECONOMICS AND HEALTH POLICY, 2022, 20 (03) : 305 - 313
  • [45] UroLift for Treating Lower Urinary Tract Symptoms of Benign Prostatic Hyperplasia: A NICE Medical Technology Guidance Update
    Laura Knight
    Megan Dale
    Andrew Cleves
    Charlotte Pelekanou
    Rhys Morris
    Applied Health Economics and Health Policy, 2022, 20 : 669 - 680
  • [46] WatchBP Home A for opportunistically detecting atrial fibrillation during diagnosis and monitoring of hypertension: A NICE medical technology guidance
    Willits I.
    Keltie K.
    Craig J.
    Sims A.
    Applied Health Economics and Health Policy, 2014, 12 (3) : 255 - 265
  • [47] UroLift for Treating Lower Urinary Tract Symptoms of Benign Prostatic Hyperplasia: A NICE Medical Technology Guidance Update
    Knight, Laura
    Dale, Megan
    Cleves, Andrew
    Pelekanou, Charlotte
    Morris, Rhys
    APPLIED HEALTH ECONOMICS AND HEALTH POLICY, 2022, 20 (05) : 669 - 680
  • [48] PleurX Peritoneal Catheter Drainage System for Vacuum-Assisted Drainage of Treatment-Resistant, Recurrent Malignant Ascites A NICE Medical Technology Guidance
    White, Judith
    Carolan-Rees, Grace
    APPLIED HEALTH ECONOMICS AND HEALTH POLICY, 2012, 10 (05) : 299 - 308
  • [49] PleurX Peritoneal Catheter Drainage System for Vacuum-Assisted Drainage of Treatment-Resistant, Recurrent Malignant AscitesA NICE Medical Technology Guidance
    Judith White
    Grace Carolan-Rees
    Applied Health Economics and Health Policy, 2012, 10 (5) : 299 - 308
  • [50] Re: Axonics Sacral Neuromodulation System for Treating Refractory Overactive Bladder: A NICE Medical Technologies Guidance
    Wein, Alan J.
    JOURNAL OF UROLOGY, 2022, 207 (06): : 1354 - 1355